Recept No	First Name	Last Name	Program No	Session	Session Title	Date	Time	Order	Area	Abstract Title
10132	Hidekatsu	Fukuta	PJ026-1	ポスターセッション(日本語) 026	Heart failure (pharmacology/non- pharmacology)	3/23 (Fri)	16:50-17:40	1	10F Poster Room	The Effect of Influenza Vaccination on Mortality and Hospitalization in Patients with Heart Failure: A Meta-Analysis
10168	Yusuke	Nakano	PE026-3	Poster Session(English) 026	Heart failure (pharmacology) 1	3/23 (Fri)	15:00-15:50	3	10F Poster Room	Impact of Loop Diuretics Dose Used along with Tolvaptan on Worsening of Renal Function
10237	Shunsuke	Kiuchi	PJ023-3	ポスターセッション(日本語) 023	Heart failure (pharmacology)	3/23 (Fri)	16:50-17:40	3	10F Poster Room	The Relationship between the Time until Commencement of Tolvaptan and the Length of Hospital Stay in Heart Failure Patients
10246	Tetsuo	Yamaguchi	PE160-7	Poster Session(English) 160	Heart failure (pharmacology) 3	3/25 (Sun)	15:50-16:40	7	10F Poster Room	Prognostic Impact of Optimizing Guideline-directed Medical Therapy before Discharge in Patients Hospitalized with Acute Heart Failure with Reduced Fiection Fraction
10418	Meihua	Li	PE160-6	Poster Session(English) 160	Heart failure (pharmacology) 3	3/25 (Sun)	15:50-16:40	6	10F Poster Room	Donepezil Markedly Prevents the Progression of Chronic Heart Failure in Spontaneously Hypertensive Rats with Myocardial Infarction
10421	Meihua	Li	OE77-2	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	2	Room 7	Donepezil Markedly Prevents the Progression of Cardiac Remodeling in Obesity-induced Hypertensive Rats with Reperfused Myocardial Infarction
10495	Chikayuki	Ito	PJ026-2	ポスターセッション(日本語) 026	Heart failure (pharmacology/non- pharmacology)	3/23 (Fri)	16:50-17:40	2	10F Poster Room	Long-term efficacy and safety of Tolvaptan in outpatients with heart failure after discharge
10587	Yuichi	Kato	OE77-9	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	9	Room 7	Hospitalization Period Could be Significantly Shortened by the Clinical Pathway with Early Administration of Tolvaptan in Congestive Heart Failure Cases.
10604	Naoaki	Matsuo	PE105-2	Poster Session(English) 105	Heart failure (pharmacology) 2	3/24 (Sat)	18:00-18:50	2	10F Poster Room	The Clinical Pathway with Early Administration of Tolvaptan was Useful and Safe Even in Super-Elder Patients with Congestive Heart Failure
10610	Yuichi	Kato	PE026-6	Poster Session(English) 026	Heart failure (pharmacology) 1	3/23 (Fri)	15:00-15:50	6	10F Poster Room	The Peculiar Factor Contributed to the Occurrence of Adverse Events Related to Use of Tolvaptan in Congestive Heart Failure Cases.
10959	Shinya	Suzuki	PE105-4	Poster Session(English) 105	Heart failure (pharmacology) 2	3/24 (Sat)	18:00-18:50	4	10F Poster Room	Association between bisoprolol serum concentration and left ventricular reverse remodeling in patients with reduced ejection fraction (CVI ARO 6)
11132	Kyohhei	Marume	PE160-5	Poster Session(English) 160	Heart failure (pharmacology) 3	3/25 (Sun)	15:50-16:40	5	10F Poster Room	The Effect of Statins on Mortality in Patients with Heart Failure with Preserved Ejection Fraction -A Report From the JASPER-Study
11165	Hiroaki	Kawano	PE105-3	Poster Session(English) 105	Heart failure (pharmacology) 2	3/24 (Sat)	18:00-18:50	3	10F Poster Room	Comparison of Efficacy Criteria between Tolvaptan and Carperitide for the Treatment for Acute exacerbation of Chronic Heart Failure
11248	Tatsuaki	Murakami	PE160-3	Poster Session(English) 160	Heart failure (pharmacology) 3	3/25 (Sun)	15:50-16:40	3	10F Poster Room	Empagliflozin Early Reverses Metabolic and Cardiac Dysfunction in Type-2 Diabetics with Chronic Heart Failure
11254	Go	Kawamura	PJ023-6	ポスターセッション(日本語) 023	Heart failure (pharmacology)	3/23 (Fri)	16:50-17:40	6	10F Poster Room	Favorable Effects of Early Tolvaptan Administration in Very Elderly Patients after Repeat Hospitalizations for Acute Decompensated Heart Failure.
11309	Yuko	Matsui	OE77-3	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	3	Room 7	Use of Mineralocorticoid Receptor Antagonists in Real-world Heart Failure Patients with Reduced Ejection Fraction: an Analysis of HIJ-HF II Study
11342	Hiroki	Chiba	OJ20-7	一般演題口述(日本語) 20	Heart failure (pathophysiology/pharmacology)	3/25 (Sun)	10:50-12:00	7	Room 8	Validation Study for Intra-Renal Venous Doppler as the Visual Biomarker of Renal Congestion Using a Hypertensive Heart Failure
11359	Naoko P.	Kato	OE54-7	Oral Presentation(English) 54	Heart failure (pathophysiology/pharmacology)	3/24 (Sat)	13:50-15:00	7	Room 5	Relationship of Mineralocorticoid Receptor Antagonists with Mortality among Heart Failure Patients with Beta-blockers
11438	Taishi	Nakamura	OE77-7	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	7	Room 7	PKG1α Disulfide Formation by Oxidation Facilitates Anti- hypertrophic/Anti-fibrotic Effects from PDE5 Inhibition but not sGC Activation
11440	Hideki	Tokuhisa	PE026-7	Poster Session(English) 026	Heart failure (pharmacology) 1	3/23 (Fri)	15:00-15:50	7	10F Poster Room	Lipophilic statin, but hydrophilic not, reduced muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction
11488	Yusuke	Uemura	OE77-8	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	8	Room 7	Clinical Benefit of Long-term Use of Tolvaptan after Discharge in Patients with Heart Failure and Chronic Kidney Disease
11527	Koichiro	Kinugawa	PE026-4	Poster Session(English) 026	Heart failure (pharmacology) 1	3/23 (Fri)	15:00-15:50	4	10F Poster Room	Effects of Tolvaptan on Volume Overload in Patients with Heart Failure: Meta-Analysis of Randomized Controlled Trials

Recept No	First Name	Last Name	Program No	Session	Session Title	Date	Time	Order	Area	Abstract Title
11563	Satoshi	Higuchi	OE77-4	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	4	Room 7	Long-Term Impact of Renin-angiotensin System Inhibitors Depending on the Renal Function in the Setting of Systolic Heart Failure
11763	Daisuke	Maebuchi	PJ040-6	ポスターセッション(日本語) 040	Heart Failure	3/24 (Sat)	16:30-17:20	6	10F Poster Room	Estimated urine osmolality can predict the effect of Tolvaptan on the treatment of decompensated heart failure
11769	Masaki	Nakagaito	OJ20-5	一般演題口述(日本語) 20	Heart failure (pathophysiology/pharmacology)	3/25 (Sun)	10:50-12:00	5	Room 8	Effect of Sodium-glucose Cotransporter 2 Inhibitors in Combination with Loop Diuretics on Neurohumoral Factor in Heart Failure Patients with Diabetes
11875	Shinya	Suzuki	OE77-5	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	5	Room 7	Association between dose and serum concentration of bisoprolol in patients with heart failure (CVI ARO 6)
12050	Jun	Shitara	PJ023-1	ポスターセッション(日本語) 023	Heart failure (pharmacology)	3/23 (Fri)	16:50-17:40	1	10F Poster Room	Differing Effects of Beta-Blockers on Long-term Clinical Outcomes Following Percutaneous Coronary Intervention between Patients with Mid-range and Reduced Fiection Fraction.
12076	Shunsuke	Tamaki	PE026-1	Poster Session(English) 026	Heart failure (pharmacology) 1	3/23 (Fri)	15:00-15:50	1	10F Poster Room	Effect of Tolvaptan Therapy on Cardiac Sympathetic Nerve Activity in Patients With Acute Decompensated Heart Failure and Preserved
12156	Wataru	Takahashi	PJ023-4	ポスターセッション(日本語) 023	Heart failure (pharmacology)	3/23 (Fri)	16:50-17:40	4	10F Poster Room	The Characteristics of the Clinical Effects of Carvedilol to the Elderly Patients with Chronic Systolic Heart Failure
12254	Kenta	Masada	OE33-7	Oral Presentation(English) 33	Heart failure (basic/pharmacology), Regeneration (basic, clinical)	3/23 (Fri)	13:20-14:50	7	Room 8	Sustained-release Synthetic Prostacyclin Agonist Attenuates Pressure Overload-induced Cardiac Fibrosis by Inhibiting Fibroblast Activation in Mice
12300	Kazuyoshi	Toda	OJ20-6	一般演題口述(日本語) 20	Heart failure (pathophysiology/pharmacology)	3/25 (Sun)	10:50-12:00	6	Room 8	Effects of Selective Aldosterone Blocker Eplerenone on Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Chronic Heart Failure
12330	Koichiro	Kinugawa	PE026-2	Poster Session(English) 026	Heart failure (pharmacology) 1	3/23 (Fri)	15:00-15:50	2	10F Poster Room	Characteristics of patients with dyspnea improved by tolvaptan treatment
12381	Kimiko	Nagara	PE105-5	Poster Session(English) 105	Heart failure (pharmacology) 2	3/24 (Sat)	18:00-18:50	5	10F Poster Room	Long-term Survival in Heart Failure Patients Receiving Carvedilol Therpay: a 10-Year Observational Study
12611	Tomoaki	Saeki	PJ040-5	ポスターセッション(日本語) 040	Heart Failure	3/24 (Sat)	16:30-17:20	5	10F Poster Room	Urinary Sodium and Potassium Excretion Ratio and Plasma BNP Level in Patients with Compensated Heart Failure
12759	Yosuke	Inoue	PE136-7	Poster Session(English) 136	Heart failure (pharmacology/non- pharmacology)	3/25 (Sun)	14:00-14:50	7	10F Poster Room	Effectiveness of Long-Term Administration of Low Dose Tolvaptan
12922	Ryu	Shutta	PE160-4	Poster Session(English) 160	Heart failure (pharmacology) 3	3/25 (Sun)	15:50-16:40	4	10F Poster Room	Beneficial Effect of Statin in Non-ischemic Patients with Heart Failure with Preserved Ejection Fraction
13016	Noriaki	Iwahashi	PE105-6	Poster Session(English) 105	Heart failure (pharmacology) 2	3/24 (Sat)	18:00-18:50	6	10F Poster Room	Hemodynamic Effectiveness and Clinical Usefulness of Landiolol for rapid Atrial Fibrillation in ADHF
13060	Takeshi	Soeki	OE77-1	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	1	Room 7	C-type natriuretic peptide improves left ventricular diastolic dysfunction in HFpEF model rats
13129	Kazuoki	Dai	PE105-1	Poster Session(English) 105	Heart failure (pharmacology) 2	3/24 (Sat)	18:00-18:50	1	10F Poster Room	Incidence and Predictors of Adverse Events after Tolvaptan Administration in Patients with Acute Decompensated Heart Failure
13501	Takahiro	Kamihara	PE160-1	Poster Session(English) 160	Heart failure (pharmacology) 3	3/25 (Sun)	15:50-16:40	1	10F Poster Room	SGLT2 inhibition ameliorates diabetic cardiomyopathy in mice via elevation of Gcg in a insulin-dependent fashion.
13527	Shigeru	Toyoda	PJ023-5	ポスターセッション(日本語) 023	Heart failure (pharmacology)	3/23 (Fri)	16:50-17:40	5	10F Poster Room	Influence of long-acting versus short-acting loop diuretics on long- term clinical outcomes in patients with chronic heart failure
13593	Yodo	Tamaki	OE77-6	Oral Presentation(English) 77	Heart failure (pharmacology)	3/25 (Sun)	15:10-16:40	6	Room 7	Effects of Beta Blocker Use Prior to Admission in Patients with Acute Decompensated Heart Failure
13603	Yoshie	Haga	PJ023-2	ポスターセッション(日本語) 023	Heart failure (pharmacology)	3/23 (Fri)	16:50-17:40	2	10F Poster Room	Efficacy and Safety of Tolvaptan for Very Elderly Patients with Acute Heart Failure
13634	Kensuke	Takabayashi	OE54-6	Oral	Heart failure (pathophysiology/pharmacology)	3/24 (Sat)	13:50-15:00	6	Room 5	Polypharmacy and Multiple Times of Medication are the Independent Risk of Rehospitalization for Heart Failure in Patient with Heart Failure

51.Heart failure (pharmacology)

Recept No	First Name	Last Name	Program No	Session	Session Title	Date	Time	Order	Area	Abstract Title
13651	Yasuhiro	Ikeda	PE160-2	Poster Session(English) 160	Heart failure (pharmacology) 3	3/25 (Sun)	15:50-16:40	2	10F Poster Room	Yin and Yang Effects of Sodium Glucose Co-transporter 2 inhibitors in Japanese Patients with Diabetic Heart Failure
13743	Shintarou	Dobashi	PE105-7	Poster Session(English) 105	Heart failure (pharmacology) 2	3/24 (Sat)	18:00-18:50	7	10F Poster Room	Coexisting Ischemic Heart Disease Determines the Optimal Choice of Phosphodiesterase3- inhibitor in Patients with Decompensated Heart Failure
13773	Keiko	Fukino	PE026-5	Poster Session(English) 026	Heart failure (pharmacology) 1	3/23 (Fri)	15:00-15:50	5	10F Poster Room	Clinical Impact of Additional Tolvaptan to Conventional Diuretic Therapy in Hospitalized Patients with Acute Heart Failure and Impaired Renal Function
20157	Jong Shin	Woo	OE54-5	Oral Presentation(English) 54	Heart failure (pathophysiology/pharmacology)	3/24 (Sat)	13:50-15:00	5	Room 5	Effect of Vitamin D on Endothelial Function in patients with Chronic Heart Failure